Surmodics, Inc. (SRDX)
NASDAQ: SRDX · Real-Time Price · USD
37.51
-0.29 (-0.77%)
Oct 29, 2024, 4:00 PM EDT - Market closed

Company Description

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally.

It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths.

The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets.

This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Surmodics, Inc.
Surmodics logo
Country United States
Founded 1979
IPO Date Mar 4, 1998
Industry Medical Devices
Sector Healthcare
Employees 376
CEO Gary Maharaj

Contact Details

Address:
9924 West 74th Street
Eden Prairie, Minnesota 55344-3523
United States
Phone 952 500 7000
Website surmodics.com

Stock Details

Ticker Symbol SRDX
Exchange NASDAQ
Fiscal Year October - September
Reporting Currency USD
CIK Code 0000924717
CUSIP Number 868873100
ISIN Number US8688731004
Employer ID 41-1356149
SIC Code 3841

Key Executives

Name Position
Gary R. Maharaj Chief Executive Officer, President and Director
Timothy J. Arens Senior Vice President of Finance and Information Technology and Chief Financial Officer
Gordon S. Weber J.D. Senior Vice President of Legal, General Counsel and Secretary
Charles W. Olson Senior Vice President and President of Medical Device Coatings
Teryl L. W. Sides Senior Vice President and President of Vascular Interventions
John D. Manders Corporate Controller, Vice President of Finance and Principal Accounting Officer
Joel Suiter Director of Corporate Development
Joseph J. Stich Senior Vice President of Human Resources and President of In Vitro Diagnostics

Latest SEC Filings

Date Type Title
Oct 23, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 23, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 14, 2024 8-K Current Report
Aug 13, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Aug 13, 2024 8-K Current Report
Aug 8, 2024 8-K Current Report
Jul 31, 2024 10-Q Quarterly Report
Jul 31, 2024 8-K Current Report
Jul 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jul 8, 2024 DEFM14A Filing